Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

Kent Lake Partners, an investment fund holding 2,688,472 shares of Quanterix, is urging the Quanterix board not to increase its cash offer for Akoya Biosciences, citing concerns about balance sheet risk and a potential breach of fiduciary duty. Kent Lake believes Quanterix shareholders do not support the merger, as evidenced by the amended merger terms structured to avoid a shareholder vote. They suggest Quanterix should consider selling itself instead of pursuing the Akoya acquisition at an inflated price, and are preparing a proxy solicitation for the 2025 annual meeting to elect their director nominees.

Analysis

Kent Lake Partners, a significant shareholder in Quanterix Corporation (QTRX) holding 2,688,472 shares, is actively opposing the company's amended merger agreement with Akoya BioSciences (AKYA). The core of their argument, supported by a strongly negative sentiment (-0.7 overall, -0.8 for QTRX), is that Quanterix's board is pursuing a value-destructive merger structured to circumvent a shareholder vote, despite indications that major stockholders and external advisors foresaw low approval for the original terms due to deteriorating market conditions. Kent Lake highlights concerns that increasing the cash offer for Akoya would place Quanterix's balance sheet at significant risk, especially given Quanterix's current negative enterprise value and ongoing "industry turmoil." They assert that such a move, against expressed shareholder will, would constitute a breach of fiduciary duty. Instead of further pursuing Akoya, Kent Lake suggests Quanterix should allow Akoya to entertain superior proposals or, if the board significantly undervalues Quanterix shares by proceeding, initiate a strategic alternatives process to sell Quanterix. Reflecting their serious intent, Kent Lake Partners intends to file a preliminary proxy statement for the 2025 annual meeting to nominate its own slate of directors, indicating a potential activist campaign focused on M&A strategy, corporate governance, and company fundamentals within the healthcare and biotech sector.

Key Decisions for Investors

• Investors in Quanterix (QTRX) should closely monitor the unfolding activist campaign by Kent Lake Partners and its potential impact on the proposed Akoya (AKYA) merger and board composition.
• Carefully assess the financial implications of the Akoya acquisition on Quanterix's balance sheet, particularly if the offer is increased, given the company's reported negative enterprise value and shareholder opposition.
• Consider the heightened uncertainty surrounding Quanterix's strategic direction and the potential for a proxy contest at the 2025 annual meeting, which could influence stock volatility and long-term value.
• Evaluate management's response to shareholder concerns and their justification for proceeding with a merger that appears to lack broad shareholder support and carries significant financial risk.